Asymmetric Dihydroxylations of ?-SubstitutedN-(?,?-Enoyl)bornane-10,2-sultams
作者:Wolfgang Oppolzer、Jean-Pierre Barras
DOI:10.1002/hlca.19870700703
日期:1987.11.4
Pure (E)- or (Z)-enoylsultams 2 were Oxidized with OsO4/N-Methylmorpholine N-oxide in a stereospecific and highly π-face-selective manner. Acetalization of the resulting 1,2-diols furnished, after purification, the stable, crystalline acetals 6 in >99% d.e. and in 63–74% overall yield from 2. Reductive or hydrolytic cleavage of 6 gave enantiomerically pure alcohols 8 or carboxylic acids 9 with recovery
Catalytic Asymmetric Formation of δ-Lactones from Unsaturated Acyl Halides
作者:Paolo S. Tiseni、René Peters
DOI:10.1002/chem.200902896
日期:2010.2.22
Previously unexplored enantiopure zwitterionic ammonium dienolates have been utilized in this work as reactive intermediates that act as diene components in hetero‐Diels–Alderreactions (HDAs) with aldehydes to produce optically active δ‐lactones, subunits of numerous bioactive products. The dienolates were generated in situ from E/Z mixtures of α,β‐unsaturated acid chlorides by use of a nucleophilic
Stereospecific synthesis of (Z) or (E)-3-methylalk-2-enoic acids
作者:Mohamed Abarbri、Jean-Luc Parrain、Alain Duchêne
DOI:10.1016/0040-4039(95)00285-k
日期:1995.4
The palladiumcatalysed coupling of organozinc or organotin reagents with 3-iodobut-2(or 3)-enoic acid is stereoselective and affords Z(or E)-3-methylalk-2-enoic acids. The method was applied to the synthesis of the E and Z stereoisomers of ocimenones and pseudo-tagetones.
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT
2C
receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT
2C
receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT
2C
receptor.
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.